FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

In a land­mark mo­ment for ge­net­ic med­i­cine and sick­le cell dis­ease pa­tients, the FDA on Fri­day ap­proved not just one but two gene ther­a­pies for the dis­ease: Ver­tex Phar­ma­ceu­ti­cals’ and CRISPR Ther­a­peu­tics’ Cas­gevy, mark­ing the first-ever ap­proval of a CRISPR-based med­i­cine in the US, and Lyf­ge­nia, blue­bird bio’s lentivi­ral gene ther­a­py.

The treat­ments are ap­proved for sick­le cell dis­ease pa­tients 12 years of age and old­er who ex­pe­ri­ence painful at­tacks as­so­ci­at­ed with the dis­ease. Ver­tex will charge $2.2 mil­lion in the US for Cas­gevy, while blue­bird will charge $3.1 mil­lion for Lyf­ge­nia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER